Urology News and Research

Latest Urology News and Research

Henry Ford Hospital expands research on gene and radiation therapy for prostate cancer

Henry Ford Hospital is embarking on an expanded major clinical trial involving the use of gene therapy in combination with radiation therapy, to determine if the combined treatment is more effective than radiation therapy alone for patients with intermediate risk prostate cancer.

7 Feb 2008

New cancer center at NewYork-Presbyterian/Weill Cornell

NewYork-Presbyterian Hospital/Weill Cornell Medical Center has created an expanded cancer program dedicated to advancing research, prevention and treatment of the disease. The new Cancer Center is led by renowned cancer physician-scientist Dr. Andrew Dannenberg.

5 Feb 2008

Experimental biomarker test beats PSA in detecting prostate cancer

An experimental biomarker test developed by researchers at the University of Michigan more accurately detects prostate cancer than any other screening method currently in use, according to a study published in the February 1 issue of Cancer Research, a journal of the American Association for Cancer Research.

5 Feb 2008

New nanomedicine research for prostate cancer

The Prostate Cancer Foundation, largely through the generosity of David H. Koch, has given $5 million to four institutions, including Weill Cornell Medical College, to support novel research in prostate cancer. The gift is one of the largest-ever individual donations for prostate cancer research.

29 Jan 2008

Cranberries might help prevent urinary infections in women

Evidence supports drinking cranberry juice a familiar home remedy to treat urinary tract infection (UTI), according to a new review from Scotland.

24 Jan 2008

Pros, cons of finasteride to prevent prostate cancer should be considered

Findings by UT Southwestern Medical Center researchers encourage men to weigh both the potential benefits and side effects of the drug finasteride before taking it to prevent prostate cancer.

22 Jan 2008

Prostatitis - one of the most common urologic diseases in the U.S

Estimates on the number of males in the United States who will experience prostatitis during their lifetimes range up to 50 percent.

21 Jan 2008

Gene markers located for hereditary prostate cancer

Researchers at the Johns Hopkins Brady Urological Institute, Wake Forest University and the Karolinska Institute in Sweden have identified an array of gene markers for hereditary prostate cancer that, along with family history for the disease, appear to raise risk to more than nine times that of men without such markers.

17 Jan 2008

Hormonal nutritional supplements might speed prostate cancer progression

Hormonal components in over-the-counter dietary supplements may promote the progression of prostate cancer and decrease the effectiveness of anti-cancer drugs, researchers at UT Southwestern Medical Center have discovered.

16 Jan 2008

Hormonal components in over-the-counter dietary supplements might promote prostate cancer progression

15 Jan 2008

Radical and partial nephrectomy for kidney cancers

A new Mayo Clinic study suggests that removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival compared with an operation that removes the tumor but leaves the kidney intact.

10 Jan 2008

Circumcision shown not to reduce sexual satisfaction and performance

More than 98 per cent of men who are circumcised can enjoy the same levels of sexual satisfaction and performance as men who are not, according to a study of nearly 4,500 males published in the January issue of the UK-based urology journal BJU International.

7 Jan 2008

Benefits of short-term hormonal therapy for men receiving radiation therapy for prostate cancer far outweigh the risks

Researchers report that just four months of hormonal therapy before and with standard external beam radiation therapy slowed cancer growth by as much as eight years - especially the development of bone metastases - and increased survival in older men with potentially aggressive prostate cancer.

4 Jan 2008

DAB2IP gene linked to aggressive prostate cancer

Results from two genome-wide association studies have identified a genetic variant of the DAB2IP gene that is associated with the risk of aggressive prostate cancer.

13 Dec 2007

Time to remove the stigma associated with incontinence

An independent panel convened this week by the NIH found that fewer than half of individuals experiencing fecal or urinary incontinence - the inability to control bowel movements or urination, respectively - report their symptoms to healthcare providers without being prompted.

13 Dec 2007

International team gets new award to research the causes of bladder problems that affect one in six adults

An international research project which aims to solve why some people feel the constant need to urinate - a condition that affects one in every six adults - has received a prestigious new £420,000 award from the leading UK-based urology journal and charity BJU International.

10 Dec 2007

Botox shows potential for bladder spasms and leakages

Eight years ago, Lynette Kunz suffered a severe spinal cord injury that left her a quadriplegic and sufferer of involuntary bladder contractions.

5 Dec 2007

10% of patients in NHS hospitals may experience some kind of adverse event

One in ten NHS patients comes to harm while in hospital as a result of their clinical care, suggests a study in Quality and Safety in Health Care.

2 Dec 2007

Live kidney donors report high satisfaction rates and minimal health problems

Live kidney donors suffer minimal health problems and 90 per cent would strongly encourage other people to a become a donor if a partner or family member needed a transplant, according to a study of more than 300 people published in the December issue of the UK-based urology journal BJU International.

29 Nov 2007

Wyeth receives European approval for TORISEL

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the European Commission has approved TORISEL (temsirolimus) for the first-line treatment of patients with advanced renal cell carcinoma (RCC) who have at least three of six prognostic risk factors. TORISEL is the only approved cancer therapy that specifically inhibits the mTOR (mammalian target of rapamycin) kinase, an important regulator of cell proliferation, cell growth and cell survival.

27 Nov 2007